Adaptation of TeamBest FDG Technology Applied to Novel Prostate Cancer Specific Tracers

TeamBest FDG 技术应用于新型前列腺癌特异性示踪剂

基本信息

批准号：
560741-2020
负责人：
Marquardt, Drew
金额：
$ 2.19万
依托单位：
University of Windsor
依托单位国家：
加拿大
项目类别：
Alliance Grants
财政年份：
2020
资助国家：
加拿大
起止时间：
2020-01-01 至 2021-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=707187
关键词：
Adaptation TeamBest FDG Technology Applied

项目摘要

The usefulness of positron emission tomography (PET) imaging is best demonstrated by current data suggesting that in as many as one-third to one-half of cancer cases, physicians who do not have access to PET may be choosing the wrong management or treatment strategy for their patients. PET imaging relies on radiopharmaceuticals label with a radioactive element that decays through positron emmission. By far the most common radioisotope used for PET imagine is fluorine-18. The isotope fluorine-18 decays rapidly, with a half-life of 110 minutes. Such a short half-life makes shipping the radiotracers long distances expensive and often impractical. Thus synthesis of the radiopharmaceutical is ideally performed at the source of of fluorine 18. Although 96% of PET scans are perfomed with fluorodeoxyglucose (FDG), this particular radiotracer is non-specific and not ideal when monitior specific types of cancers. A up-and-coming PET approach is the use of Prostate specific membrane antigen imaging (PSMA). PSMA PET is very sensitive for detecting prostate cancer and is currently used in patients with new diagnosis of high-risk prostate cancer and those with biochemical recurrence. Thus, a reliable and expedient synthesis method of PSMA related PET agents is of high interest to the medical industry.

当前数据表明，正电子发射断层扫描（PET）成像的有用性最好证明，在多达三分之一至一半的癌症病例中，无法使用PET的医生可能会为患者选择错误的管理或治疗策略。宠物成像依靠放射性药物标签，其放射性元素通过positron提交而衰减。迄今为止，最常见的放射性同位素想象是氟18。同位素氟-18迅速衰减，半衰期为110分钟。如此短的半衰期使运输放射性示例的运输距离很昂贵，而且通常不切实际。因此，理想地在氟18的来源进行了放射性药物的合成。尽管有96％的PET扫描被氟脱氧葡萄糖（FDG）完善，但是当单型特异性类型的癌症类型时，这种特殊的放射性示例是非特异性的，并且不是理想的。新兴的宠物方法是使用前列腺特异性膜抗原成像（PSMA）。 PSMA PET对检测前列腺癌非常敏感，目前用于具有新诊断的高危前列腺癌和生化复发的患者。因此，与PSMA相关的宠物代理商的可靠且权宜的合成方法对医疗行业具有很高的兴趣。